Skip to main content
Top
Published in: Pediatric Nephrology 5/2018

Open Access 01-05-2018 | Review

New insights into the pathogenesis of IgA nephropathy

Authors: See Cheng Yeo, Chee Kay Cheung, Jonathan Barratt

Published in: Pediatric Nephrology | Issue 5/2018

Login to get access

Abstract

IgA nephropathy is the most common form of glomerulonephritis in many parts of the world and remains an important cause of end-stage renal disease. Current evidence suggests that IgA nephropathy is not due to a single pathogenic insult, but rather the result of multiple sequential pathogenic “hits”. An abnormally increased level of circulating poorly O-galactosylated IgA1 and the production of O-glycan-specific antibodies leads to the formation of IgA1-containing immune complexes, and their subsequent mesangial deposition results in inflammation and glomerular injury. While this general framework has formed the foundation of our current understanding of the pathogenesis of IgA nephropathy, much work is ongoing to try to precisely define the genetic, epigenetic, immunological, and molecular basis of IgA nephropathy. In particular, the precise origin of poorly O-galactosylated IgA1 and the inciting factors for the production of O-glycan-specific antibodies continue to be intensely evaluated. The mechanisms responsible for mesangial IgA1 deposition and subsequent renal injury also remain incompletely understood. In this review, we summarize the current understanding of the key steps involved in the pathogenesis of IgA nephropathy. It is hoped that further advances in our understanding of this common glomerulonephritis will lead to novel diagnostic and prognostic biomarkers, and targeted therapies to ameliorate disease progression.
Literature
1.
go back to reference Berger J, Hinglais N (1968) Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris) 74:694–695 Berger J, Hinglais N (1968) Intercapillary deposits of IgA-IgG. J Urol Nephrol (Paris) 74:694–695
3.
go back to reference D'Amico G (2004) Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24:179–196PubMedCrossRef D'Amico G (2004) Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Semin Nephrol 24:179–196PubMedCrossRef
4.
go back to reference Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, Liu Z (2012) Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 27:1479–1485PubMedCrossRef Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, Liu Z (2012) Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant 27:1479–1485PubMedCrossRef
5.
go back to reference Zuo L, Wang M, Chinese Association of Blood Purification Management of Chinese Hospital A (2010) Current burden and probable increasing incidence of ESRD in China. Clin Nephrol 74(Suppl 1):S20–S22PubMed Zuo L, Wang M, Chinese Association of Blood Purification Management of Chinese Hospital A (2010) Current burden and probable increasing incidence of ESRD in China. Clin Nephrol 74(Suppl 1):S20–S22PubMed
7.
go back to reference Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795–1803PubMedPubMedCentralCrossRef Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA (2011) The pathophysiology of IgA nephropathy. J Am Soc Nephrol 22:1795–1803PubMedPubMedCentralCrossRef
8.
go back to reference Berger J, Yaneva H, Nabarra B, Barbanel C (1975) Recurrence of mesangial deposition of IgA after renal transplantation. Kidney Int 7:232–241PubMedCrossRef Berger J, Yaneva H, Nabarra B, Barbanel C (1975) Recurrence of mesangial deposition of IgA after renal transplantation. Kidney Int 7:232–241PubMedCrossRef
9.
10.
go back to reference Silva FG, Chander P, Pirani CL, Hardy MA (1982) Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation 33:241–246PubMed Silva FG, Chander P, Pirani CL, Hardy MA (1982) Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation 33:241–246PubMed
11.
go back to reference Cheung CK, Barratt J (2015) Is IgA nephropathy a single disease? In: Tomino Y (ed) Pathogenesis and treatment in IgA nephropathy. Springer, Japan, pp 3–17 Cheung CK, Barratt J (2015) Is IgA nephropathy a single disease? In: Tomino Y (ed) Pathogenesis and treatment in IgA nephropathy. Springer, Japan, pp 3–17
12.
go back to reference Waldherr R, Rambausek M, Duncker WD, Ritz E (1989) Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 4:943–946PubMedCrossRef Waldherr R, Rambausek M, Duncker WD, Ritz E (1989) Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 4:943–946PubMedCrossRef
13.
go back to reference Varis J, Rantala I, Pasternack A, Oksa H, Jantti M, Paunu ES, Pirhonen R (1993) Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol 46:607–610PubMedPubMedCentralCrossRef Varis J, Rantala I, Pasternack A, Oksa H, Jantti M, Paunu ES, Pirhonen R (1993) Immunoglobulin and complement deposition in glomeruli of 756 subjects who had committed suicide or met with a violent death. J Clin Pathol 46:607–610PubMedPubMedCentralCrossRef
14.
go back to reference Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y (2003) Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63:2286–2294PubMedCrossRef Suzuki K, Honda K, Tanabe K, Toma H, Nihei H, Yamaguchi Y (2003) Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63:2286–2294PubMedCrossRef
15.
go back to reference Coppo R (2017) Biomarkers and targeted new therapies for IgA nephropathy. Pediatr Nephrol 32:725–731PubMedCrossRef Coppo R (2017) Biomarkers and targeted new therapies for IgA nephropathy. Pediatr Nephrol 32:725–731PubMedCrossRef
16.
go back to reference Yeo SC, Liew A, Barratt J (2015) Emerging therapies in immunoglobulin a nephropathy. Nephrology 20:788–800PubMedCrossRef Yeo SC, Liew A, Barratt J (2015) Emerging therapies in immunoglobulin a nephropathy. Nephrology 20:788–800PubMedCrossRef
17.
go back to reference Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J (2007) Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71:1148–1154PubMedCrossRef Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J (2007) Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int 71:1148–1154PubMedCrossRef
18.
go back to reference Allen AC, Bailey EM, Brenchley PE, Buck KS, Barratt J, Feehally J (2001) Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 60:969–973 Allen AC, Bailey EM, Brenchley PE, Buck KS, Barratt J, Feehally J (2001) Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int 60:969–973
19.
go back to reference Allen AC, Bailey EM, Barratt J, Buck KS, Feehally J (1999) Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol 10:1763–1771PubMed Allen AC, Bailey EM, Barratt J, Buck KS, Feehally J (1999) Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis. J Am Soc Nephrol 10:1763–1771PubMed
20.
go back to reference Hiki Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H, Shinzato T, Kobayashi Y, Maeda K (2001) Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 59:1077–1085PubMedCrossRef Hiki Y, Odani H, Takahashi M, Yasuda Y, Nishimoto A, Iwase H, Shinzato T, Kobayashi Y, Maeda K (2001) Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney Int 59:1077–1085PubMedCrossRef
21.
go back to reference Coppo R, Amore A (2004) Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int 65:1544–1547PubMedCrossRef Coppo R, Amore A (2004) Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int 65:1544–1547PubMedCrossRef
22.
go back to reference Xu LX, Zhao MH (2005) Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int 68:167–172PubMedCrossRef Xu LX, Zhao MH (2005) Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int 68:167–172PubMedCrossRef
23.
go back to reference Woof JM, Russell MW (2011) Structure and function relationships in IgA. Mucosal Immunol 4:590–597PubMedCrossRef Woof JM, Russell MW (2011) Structure and function relationships in IgA. Mucosal Immunol 4:590–597PubMedCrossRef
24.
go back to reference Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Edberg JC, Alarcon GS, Kimberly RP, Tomino Y, Mestecky J, Novak J (2008) IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 118:629–639PubMedPubMedCentral Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, Julian BA, Tomana M, Wyatt RJ, Edberg JC, Alarcon GS, Kimberly RP, Tomino Y, Mestecky J, Novak J (2008) IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest 118:629–639PubMedPubMedCentral
25.
go back to reference Raska M, Moldoveanu Z, Suzuki H, Brown R, Kulhavy R, Andrasi J, Hall S, Vu HL, Carlsson F, Lindahl G, Tomana M, Julian BA, Wyatt RJ, Mestecky J, Novak J (2007) Identification and characterization of CMP-NeuAc:GalNAc-IgA1 alpha2,6-sialyltransferase in IgA1-producing cells. J Mol Biol 369:69–78PubMedPubMedCentralCrossRef Raska M, Moldoveanu Z, Suzuki H, Brown R, Kulhavy R, Andrasi J, Hall S, Vu HL, Carlsson F, Lindahl G, Tomana M, Julian BA, Wyatt RJ, Mestecky J, Novak J (2007) Identification and characterization of CMP-NeuAc:GalNAc-IgA1 alpha2,6-sialyltransferase in IgA1-producing cells. J Mol Biol 369:69–78PubMedPubMedCentralCrossRef
26.
go back to reference Franc V, Rehulka P, Raus M, Stulik J, Novak J, Renfrow MB, Sebela M (2013) Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing. J Proteome 92:299–312CrossRef Franc V, Rehulka P, Raus M, Stulik J, Novak J, Renfrow MB, Sebela M (2013) Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing. J Proteome 92:299–312CrossRef
27.
go back to reference Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, Kaneko E, Tomino Y (2015) Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant 30:1315–1321PubMedPubMedCentralCrossRef Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, Kaneko E, Tomino Y (2015) Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant 30:1315–1321PubMedPubMedCentralCrossRef
28.
go back to reference Yamada K, Kobayashi N, Ikeda T, Suzuki Y, Tsuge T, Horikoshi S, Emancipator SN, Tomino Y (2010) Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant 25:3890–3897PubMedPubMedCentralCrossRef Yamada K, Kobayashi N, Ikeda T, Suzuki Y, Tsuge T, Horikoshi S, Emancipator SN, Tomino Y (2010) Down-regulation of core 1 beta1,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant 25:3890–3897PubMedPubMedCentralCrossRef
29.
go back to reference Li GS, Zhang H, Lv JC, Shen Y, Wang HY (2007) Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int 71:448–453PubMedCrossRef Li GS, Zhang H, Lv JC, Shen Y, Wang HY (2007) Variants of C1GALT1 gene are associated with the genetic susceptibility to IgA nephropathy. Kidney Int 71:448–453PubMedCrossRef
30.
go back to reference Inoue T, Sugiyama H, Kikumoto Y, Fukuoka N, Maeshima Y, Hattori H, Fukushima K, Nishizaki K, Hiki Y, Makino H (2007) Downregulation of the beta1,3- galactosyltransferase gene in tonsillar B lymphocytes and aberrant lectin bindings to tonsillar IgA as a pathogenesis of IgA nephropathy. Contrib Nephrol 157:120–124PubMed Inoue T, Sugiyama H, Kikumoto Y, Fukuoka N, Maeshima Y, Hattori H, Fukushima K, Nishizaki K, Hiki Y, Makino H (2007) Downregulation of the beta1,3- galactosyltransferase gene in tonsillar B lymphocytes and aberrant lectin bindings to tonsillar IgA as a pathogenesis of IgA nephropathy. Contrib Nephrol 157:120–124PubMed
31.
go back to reference Smith AC, de Wolff JF, Molyneux K, Feehally J, Barratt J (2006) O-glycosylation of serum IgD in IgA nephropathy. J Am Soc Nephrol 17:1192–1199PubMedCrossRef Smith AC, de Wolff JF, Molyneux K, Feehally J, Barratt J (2006) O-glycosylation of serum IgD in IgA nephropathy. J Am Soc Nephrol 17:1192–1199PubMedCrossRef
32.
go back to reference Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, Gharavi AG, Novak J, Zhang H (2012) The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82:790–796PubMedPubMedCentralCrossRef Zhao N, Hou P, Lv J, Moldoveanu Z, Li Y, Kiryluk K, Gharavi AG, Novak J, Zhang H (2012) The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int 82:790–796PubMedPubMedCentralCrossRef
33.
go back to reference Lomax-Browne HJ, Visconti A, Pusey CD, Cook HT, Spector TD, Pickering MC, Falchi M (2017) IgA1 glycosylation is heritable in healthy twins. J Am Soc Nephrol 28:64–68PubMedCrossRef Lomax-Browne HJ, Visconti A, Pusey CD, Cook HT, Spector TD, Pickering MC, Falchi M (2017) IgA1 glycosylation is heritable in healthy twins. J Am Soc Nephrol 28:64–68PubMedCrossRef
34.
go back to reference Hastings MC, Moldoveanu Z, Julian BA, Novak J, Sanders JT, McGlothan KR, Gharavi AG, Wyatt RJ (2010) Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol 5:2069–2074PubMedPubMedCentralCrossRef Hastings MC, Moldoveanu Z, Julian BA, Novak J, Sanders JT, McGlothan KR, Gharavi AG, Wyatt RJ (2010) Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol 5:2069–2074PubMedPubMedCentralCrossRef
35.
go back to reference Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, Mestecky J, Novak J, Julian BA (2008) Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19:1008–1014PubMedPubMedCentralCrossRef Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, Mestecky J, Novak J, Julian BA (2008) Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol 19:1008–1014PubMedPubMedCentralCrossRef
36.
go back to reference Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, Novak J, Gharavi AG, Wyatt RJ (2011) Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch–Schönlein purpura nephritis. Kidney Int 80:79–87PubMedPubMedCentralCrossRef Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, Novak J, Gharavi AG, Wyatt RJ (2011) Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch–Schönlein purpura nephritis. Kidney Int 80:79–87PubMedPubMedCentralCrossRef
37.
go back to reference Lin X, Ding J, Zhu L, Shi S, Jiang L, Zhao M, Zhang H (2009) Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy. Nephrol Dial Transplant 24:3372–3375PubMedCrossRef Lin X, Ding J, Zhu L, Shi S, Jiang L, Zhao M, Zhang H (2009) Aberrant galactosylation of IgA1 is involved in the genetic susceptibility of Chinese patients with IgA nephropathy. Nephrol Dial Transplant 24:3372–3375PubMedCrossRef
38.
go back to reference Gale DP, Molyneux K, Wimbury D, Higgins P, Levine AP, Caplin B, Ferlin A, Yin P, Nelson CP, Stanescu H, Samani NJ, Kleta R, Yu X, Barratt J (2017) Galactosylation of IgA1 is associated with common variation in C1GALT1. J Am Soc Nephrol Gale DP, Molyneux K, Wimbury D, Higgins P, Levine AP, Caplin B, Ferlin A, Yin P, Nelson CP, Stanescu H, Samani NJ, Kleta R, Yu X, Barratt J (2017) Galactosylation of IgA1 is associated with common variation in C1GALT1. J Am Soc Nephrol
39.
go back to reference Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, Shapiro S, LeDesma RA, Bradbury D, Ionita-Laza I, Eitner F, Rauen T, Maillard N, Berthoux F, Floege J, Chen N, Zhang H, Scolari F, Wyatt RJ, Julian BA, Gharavi AG, Novak J (2017) GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet 13:e1006609PubMedPubMedCentralCrossRef Kiryluk K, Li Y, Moldoveanu Z, Suzuki H, Reily C, Hou P, Xie J, Mladkova N, Prakash S, Fischman C, Shapiro S, LeDesma RA, Bradbury D, Ionita-Laza I, Eitner F, Rauen T, Maillard N, Berthoux F, Floege J, Chen N, Zhang H, Scolari F, Wyatt RJ, Julian BA, Gharavi AG, Novak J (2017) GWAS for serum galactose-deficient IgA1 implicates critical genes of the O-glycosylation pathway. PLoS Genet 13:e1006609PubMedPubMedCentralCrossRef
40.
go back to reference Serino G, Sallustio F, Cox SN, Pesce F, Schena FP (2012) Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol 23:814–824PubMedPubMedCentralCrossRef Serino G, Sallustio F, Cox SN, Pesce F, Schena FP (2012) Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol 23:814–824PubMedPubMedCentralCrossRef
41.
go back to reference Feehally J, Beattie TJ, Brenchley PE, Coupes BM, Mallick NP, Postlethwaite RJ (1986) Sequential study of the IgA system in relapsing IgA nephropathy. Kidney Int 30:924–931PubMedCrossRef Feehally J, Beattie TJ, Brenchley PE, Coupes BM, Mallick NP, Postlethwaite RJ (1986) Sequential study of the IgA system in relapsing IgA nephropathy. Kidney Int 30:924–931PubMedCrossRef
42.
go back to reference Conley ME, Cooper MD, Michael AF (1980) Selective deposition of immunoglobulin A1 in immunoglobulin a nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 66:1432–1436PubMedPubMedCentralCrossRef Conley ME, Cooper MD, Michael AF (1980) Selective deposition of immunoglobulin A1 in immunoglobulin a nephropathy, anaphylactoid purpura nephritis, and systemic lupus erythematosus. J Clin Invest 66:1432–1436PubMedPubMedCentralCrossRef
43.
go back to reference Layward L, Allen AC, Hattersley JM, Harper SJ, Feehally J (1994) Low antibody affinity restricted to the IgA isotype in IgA nephropathy. Clin Exp Immunol 95:35–41PubMedPubMedCentralCrossRef Layward L, Allen AC, Hattersley JM, Harper SJ, Feehally J (1994) Low antibody affinity restricted to the IgA isotype in IgA nephropathy. Clin Exp Immunol 95:35–41PubMedPubMedCentralCrossRef
44.
go back to reference Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43:321–327PubMedPubMedCentralCrossRef Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43:321–327PubMedPubMedCentralCrossRef
45.
go back to reference Harper SJ, Pringle JH, Wicks AC, Hattersley J, Layward L, Allen A, Gillies A, Lauder I, Feehally J (1994) Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int 45:836–844PubMedCrossRef Harper SJ, Pringle JH, Wicks AC, Hattersley J, Layward L, Allen A, Gillies A, Lauder I, Feehally J (1994) Expression of J chain mRNA in duodenal IgA plasma cells in IgA nephropathy. Kidney Int 45:836–844PubMedCrossRef
46.
go back to reference Harper SJ, Allen AC, Pringle JH, Feehally J (1996) Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol 49:38–42PubMedPubMedCentralCrossRef Harper SJ, Allen AC, Pringle JH, Feehally J (1996) Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA. J Clin Pathol 49:38–42PubMedPubMedCentralCrossRef
47.
go back to reference Batra A, Smith AC, Feehally J, Barratt J (2007) T-cell homing receptor expression in IgA nephropathy. Nephrol Dial Transplant 22:2540–2548PubMedCrossRef Batra A, Smith AC, Feehally J, Barratt J (2007) T-cell homing receptor expression in IgA nephropathy. Nephrol Dial Transplant 22:2540–2548PubMedCrossRef
48.
go back to reference Buren M, Yamashita M, Suzuki Y, Tomino Y, Emancipator SN (2007) Altered expression of lymphocyte homing chemokines in the pathogenesis of IgA nephropathy. Contrib Nephrol 157:50–55PubMed Buren M, Yamashita M, Suzuki Y, Tomino Y, Emancipator SN (2007) Altered expression of lymphocyte homing chemokines in the pathogenesis of IgA nephropathy. Contrib Nephrol 157:50–55PubMed
49.
go back to reference Kennel-de March A, Bene MC, Renoult E, Kessler M, Faure GC, Kolopp-Sarda MN (1999) Enhanced expression of L-selectin on peripheral blood lymphocytes from patients with IgA nephropathy. Clin Exp Immunol 115:542–546PubMedPubMedCentralCrossRef Kennel-de March A, Bene MC, Renoult E, Kessler M, Faure GC, Kolopp-Sarda MN (1999) Enhanced expression of L-selectin on peripheral blood lymphocytes from patients with IgA nephropathy. Clin Exp Immunol 115:542–546PubMedPubMedCentralCrossRef
50.
go back to reference Kennel-De March A, Bene MC, Hurault de Ligny B, Kessler M, Faure GC (1997) Enhanced expression of CD31 and CD54 on tonsillar high endothelial venules in IgA nephropathy. Clin Immunol Immunopathol 84:158–165PubMedCrossRef Kennel-De March A, Bene MC, Hurault de Ligny B, Kessler M, Faure GC (1997) Enhanced expression of CD31 and CD54 on tonsillar high endothelial venules in IgA nephropathy. Clin Immunol Immunopathol 84:158–165PubMedCrossRef
51.
go back to reference Smith AC, Molyneux K, Feehally J, Barratt J (2006) O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol 17:3520–3528PubMedCrossRef Smith AC, Molyneux K, Feehally J, Barratt J (2006) O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy. J Am Soc Nephrol 17:3520–3528PubMedCrossRef
52.
go back to reference Barratt J, Bailey EM, Buck KS, Mailley J, Moayyedi P, Feehally J, Turney JH, Crabtree JE, Allen AC (1999) Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis 33:1049–1057PubMedCrossRef Barratt J, Bailey EM, Buck KS, Mailley J, Moayyedi P, Feehally J, Turney JH, Crabtree JE, Allen AC (1999) Exaggerated systemic antibody response to mucosal Helicobacter pylori infection in IgA nephropathy. Am J Kidney Dis 33:1049–1057PubMedCrossRef
53.
go back to reference Leinikki PO, Mustonen J, Pasternack A (1987) Immune response to oral polio vaccine in patients with IgA glomerulonephritis. Clin Exp Immunol 68:33–38PubMedPubMedCentral Leinikki PO, Mustonen J, Pasternack A (1987) Immune response to oral polio vaccine in patients with IgA glomerulonephritis. Clin Exp Immunol 68:33–38PubMedPubMedCentral
54.
go back to reference Ots M, Uibo O, Metskula K, Uibo R, Salupere V (1999) IgA-antigliadin antibodies in patients with IgA nephropathy: the secondary phenomenon? Am J Nephrol 19:453–458PubMedCrossRef Ots M, Uibo O, Metskula K, Uibo R, Salupere V (1999) IgA-antigliadin antibodies in patients with IgA nephropathy: the secondary phenomenon? Am J Nephrol 19:453–458PubMedCrossRef
55.
go back to reference Feehally J, Beattie TJ, Brenchley PE, Coupes BM, Mallick NP, Postlethwaite RJ (1987) Response of circulating immune complexes to food challenge in relapsing IgA nephropathy. Pediatr Nephrol 1:581–586PubMedCrossRef Feehally J, Beattie TJ, Brenchley PE, Coupes BM, Mallick NP, Postlethwaite RJ (1987) Response of circulating immune complexes to food challenge in relapsing IgA nephropathy. Pediatr Nephrol 1:581–586PubMedCrossRef
56.
go back to reference Kennel A, Bene MC, Hurault de Ligny B, Kessler M, Faure G (1995) Serum anti-dextran antibodies in IgA nephropathy. Clin Nephrol 43:216–220PubMed Kennel A, Bene MC, Hurault de Ligny B, Kessler M, Faure G (1995) Serum anti-dextran antibodies in IgA nephropathy. Clin Nephrol 43:216–220PubMed
57.
go back to reference Floege J, Feehally J (2016) The mucosa–kidney axis in IgA nephropathy. Nat Rev Nephrol 12:147–156PubMedCrossRef Floege J, Feehally J (2016) The mucosa–kidney axis in IgA nephropathy. Nat Rev Nephrol 12:147–156PubMedCrossRef
59.
go back to reference Coppo R, Mazzucco G, Martina G, Roccatello D, Amore A, Novara R, Bargoni A, Piccoli G, Sena LM (1989) Gluten-induced experimental IgA glomerulopathy. Lab Investig 60:499–506PubMed Coppo R, Mazzucco G, Martina G, Roccatello D, Amore A, Novara R, Bargoni A, Piccoli G, Sena LM (1989) Gluten-induced experimental IgA glomerulopathy. Lab Investig 60:499–506PubMed
60.
go back to reference Papista C, Lechner S, Ben Mkaddem S, LeStang MB, Abbad L, Bex-Coudrat J, Pillebout E, Chemouny JM, Jablonski M, Flamant M, Daugas E, Vrtovsnik F, Yiangou M, Berthelot L, Monteiro RC (2015) Gluten exacerbates IgA nephropathy in humanized mice through gliadin–CD89 interaction. Kidney Int 88:276–285PubMedCrossRef Papista C, Lechner S, Ben Mkaddem S, LeStang MB, Abbad L, Bex-Coudrat J, Pillebout E, Chemouny JM, Jablonski M, Flamant M, Daugas E, Vrtovsnik F, Yiangou M, Berthelot L, Monteiro RC (2015) Gluten exacerbates IgA nephropathy in humanized mice through gliadin–CD89 interaction. Kidney Int 88:276–285PubMedCrossRef
61.
go back to reference Coppo R, Amore A, Roccatello D (1992) Dietary antigens and primary immunoglobulin a nephropathy. J Am Soc Nephrol 2:S173–S180PubMed Coppo R, Amore A, Roccatello D (1992) Dietary antigens and primary immunoglobulin a nephropathy. J Am Soc Nephrol 2:S173–S180PubMed
62.
go back to reference Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, Yamanaka T, Kanou T, Tsukaguchi H, Novak J, Horikoshi S, Tomino Y (2008) Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 19:2384–2395PubMedPubMedCentralCrossRef Suzuki H, Suzuki Y, Narita I, Aizawa M, Kihara M, Yamanaka T, Kanou T, Tsukaguchi H, Novak J, Horikoshi S, Tomino Y (2008) Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 19:2384–2395PubMedPubMedCentralCrossRef
65.
go back to reference Park HJ, Hahn WH, Suh JS, Kim MJ, Kang SW, Lee JS, Kim JW, Chung JH, Cho BS (2011) Association between Toll-like receptor 10 (TLR10) gene polymorphisms and childhood IgA nephropathy. Eur J Pediatr 170:503–509PubMedCrossRef Park HJ, Hahn WH, Suh JS, Kim MJ, Kang SW, Lee JS, Kim JW, Chung JH, Cho BS (2011) Association between Toll-like receptor 10 (TLR10) gene polymorphisms and childhood IgA nephropathy. Eur J Pediatr 170:503–509PubMedCrossRef
66.
go back to reference Qin W, Zhong X, Fan JM, Zhang YJ, Liu XR, Ma XY (2008) External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dial Transplant 23:1608–1614PubMedCrossRef Qin W, Zhong X, Fan JM, Zhang YJ, Liu XR, Ma XY (2008) External suppression causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dial Transplant 23:1608–1614PubMedCrossRef
67.
go back to reference Donadio ME, Loiacono E, Peruzzi L, Amore A, Camilla R, Chiale F, Vergano L, Boido A, Conrieri M, Bianciotto M, Bosetti FM, Coppo R (2014) Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch–Schönlein purpura and primary IgA nephropathy. Pediatr Nephrol 29:1545–1551PubMedCrossRef Donadio ME, Loiacono E, Peruzzi L, Amore A, Camilla R, Chiale F, Vergano L, Boido A, Conrieri M, Bianciotto M, Bosetti FM, Coppo R (2014) Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch–Schönlein purpura and primary IgA nephropathy. Pediatr Nephrol 29:1545–1551PubMedCrossRef
68.
go back to reference Blaas SH, Stieber-Gunckel M, Falk W, Obermeier F, Rogler G (2009) CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. Clin Exp Immunol 155:534–540PubMedPubMedCentralCrossRef Blaas SH, Stieber-Gunckel M, Falk W, Obermeier F, Rogler G (2009) CpG-oligodeoxynucleotides stimulate immunoglobulin A secretion in intestinal mucosal B cells. Clin Exp Immunol 155:534–540PubMedPubMedCentralCrossRef
69.
go back to reference Zhai YL, Zhu L, Shi SF, Liu LJ, Lv JC, Zhang H (2016) Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine (Baltimore) 95:e3099CrossRef Zhai YL, Zhu L, Shi SF, Liu LJ, Lv JC, Zhang H (2016) Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy. Medicine (Baltimore) 95:e3099CrossRef
70.
go back to reference Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, Morelli A, Ferraccioli G (2008) Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 35:1256–1264PubMed Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, Morelli A, Ferraccioli G (2008) Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 35:1256–1264PubMed
71.
go back to reference Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 109:59–68PubMedPubMedCentralCrossRef Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 109:59–68PubMedPubMedCentralCrossRef
72.
go back to reference Mackay IR, Groom J, Mackay CR (2002) Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes. Autoimmunity 35:551–553PubMedCrossRef Mackay IR, Groom J, Mackay CR (2002) Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes. Autoimmunity 35:551–553PubMedCrossRef
73.
go back to reference Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R (2003) The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 62:168–171PubMedPubMedCentralCrossRef Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R (2003) The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis 62:168–171PubMedPubMedCentralCrossRef
74.
go back to reference Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313–1319PubMedCrossRef Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313–1319PubMedCrossRef
75.
go back to reference McCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio EA, Ward L, Lawson MA, Macpherson AJ, McCoy KD, Pei Y, Novak L, Lee JY, Julian BA, Novak J, Ranger A, Gommerman JL, Browning JL (2011) Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest 121:3991–4002PubMedPubMedCentralCrossRef McCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio EA, Ward L, Lawson MA, Macpherson AJ, McCoy KD, Pei Y, Novak L, Lee JY, Julian BA, Novak J, Ranger A, Gommerman JL, Browning JL (2011) Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest 121:3991–4002PubMedPubMedCentralCrossRef
76.
go back to reference Xin G, Shi W, Xu LX, Su Y, Yan LJ, Li KS (2013) Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol 26:683–690PubMedCrossRef Xin G, Shi W, Xu LX, Su Y, Yan LJ, Li KS (2013) Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol 26:683–690PubMedCrossRef
77.
go back to reference Goto T, Bandoh N, Yoshizaki T, Nozawa H, Takahara M, Ueda S, Hayashi T, Harabuchi Y (2008) Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy. Clin Immunol 126:260–269PubMedCrossRef Goto T, Bandoh N, Yoshizaki T, Nozawa H, Takahara M, Ueda S, Hayashi T, Harabuchi Y (2008) Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CpG-ODN) in patients with IgA nephropathy. Clin Immunol 126:260–269PubMedCrossRef
78.
go back to reference Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C, Viola BF, Dallera N, Del Vecchio L, Barlassina C, Salvi E, Bertinetto FE, Amoroso A, Savoldi S, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P, Magistroni R, Ghiggeri GM, Caridi G, Bodria M, Lugani F, Allegri L, Delsante M, Maiorana M, Magnano A, Frasca G, Boer E, Boscutti G, Ponticelli C, Mignani R, Marcantoni C, Di Landro D, Santoro D, Pani A, Polci R, Feriozzi S, Chicca S, Galliani M, Gigante M, Gesualdo L, Zamboli P, Battaglia GG, Garozzo M, Maixnerova D, Tesar V, Eitner F, Rauen T, Floege J, Kovacs T, Nagy J, Mucha K, Paczek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk K, Gale D, Barratt J, Thibaudin L, Berthoux F, Canaud G, Boland A, Metzger M, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N, Zhang H, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton RP, Gharavi AG (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196PubMedPubMedCentralCrossRef Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C, Viola BF, Dallera N, Del Vecchio L, Barlassina C, Salvi E, Bertinetto FE, Amoroso A, Savoldi S, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P, Magistroni R, Ghiggeri GM, Caridi G, Bodria M, Lugani F, Allegri L, Delsante M, Maiorana M, Magnano A, Frasca G, Boer E, Boscutti G, Ponticelli C, Mignani R, Marcantoni C, Di Landro D, Santoro D, Pani A, Polci R, Feriozzi S, Chicca S, Galliani M, Gigante M, Gesualdo L, Zamboli P, Battaglia GG, Garozzo M, Maixnerova D, Tesar V, Eitner F, Rauen T, Floege J, Kovacs T, Nagy J, Mucha K, Paczek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk K, Gale D, Barratt J, Thibaudin L, Berthoux F, Canaud G, Boland A, Metzger M, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N, Zhang H, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton RP, Gharavi AG (2014) Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 46:1187–1196PubMedPubMedCentralCrossRef
79.
go back to reference Muto M, Manfroi B, Suzuki H, Joh K, Nagai M, Wakai S, Righini C, Maiguma M, Izui S, Tomino Y, Huard B, Suzuki Y (2017) Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy. J Am Soc Nephrol 28:1227–1238PubMedCrossRef Muto M, Manfroi B, Suzuki H, Joh K, Nagai M, Wakai S, Righini C, Maiguma M, Izui S, Tomino Y, Huard B, Suzuki Y (2017) Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy. J Am Soc Nephrol 28:1227–1238PubMedCrossRef
80.
go back to reference Fellstrom BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sorensen SS, Tesar V, Del Vecchio L, Investigators NT (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. doi:10.1016/S0140-6736(17)30550-0 Fellstrom BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sorensen SS, Tesar V, Del Vecchio L, Investigators NT (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. doi:10.​1016/​S0140-6736(17)30550-0
81.
go back to reference Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC (2017) A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28:1306–1313PubMedCrossRef Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC (2017) A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol 28:1306–1313PubMedCrossRef
82.
go back to reference Kyburz D, Brentano F, Gay S (2006) Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2:458–459PubMedCrossRef Kyburz D, Brentano F, Gay S (2006) Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol 2:458–459PubMedCrossRef
83.
go back to reference Ziegler HK, Unanue ER (1982) Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A 79:175–178PubMedPubMedCentralCrossRef Ziegler HK, Unanue ER (1982) Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A 79:175–178PubMedPubMedCentralCrossRef
85.
go back to reference Yanagihara T, Brown R, Hall S, Moldoveanu Z, Goepfert A, Tomana M, Julian BA, Mestecky J, Novak J (2012) In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells. Results Immunol 2:166–172PubMedPubMedCentralCrossRef Yanagihara T, Brown R, Hall S, Moldoveanu Z, Goepfert A, Tomana M, Julian BA, Mestecky J, Novak J (2012) In vitro-generated immune complexes containing galactose-deficient IgA1 stimulate proliferation of mesangial cells. Results Immunol 2:166–172PubMedPubMedCentralCrossRef
86.
go back to reference Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J (2009) Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119:1668–1677PubMedPubMedCentral Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J (2009) Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest 119:1668–1677PubMedPubMedCentral
87.
go back to reference Kokubo T, Hiki Y, Iwase H, Horii A, Tanaka A, Nishikido J, Hotta K, Kobayashi Y (1997) Evidence for involvement of IgA1 hinge glycopeptide in the IgA1-IgA1 interaction in IgA nephropathy. J Am Soc Nephrol 8:915–919PubMed Kokubo T, Hiki Y, Iwase H, Horii A, Tanaka A, Nishikido J, Hotta K, Kobayashi Y (1997) Evidence for involvement of IgA1 hinge glycopeptide in the IgA1-IgA1 interaction in IgA nephropathy. J Am Soc Nephrol 8:915–919PubMed
88.
go back to reference Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J (1997) Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 52:509–516PubMedCrossRef Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J (1997) Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 52:509–516PubMedCrossRef
89.
go back to reference Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, Makita Y, Julian BA, Novak J, Tomino Y (2014) A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One 9:e98081PubMedPubMedCentralCrossRef Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, Makita Y, Julian BA, Novak J, Tomino Y (2014) A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One 9:e98081PubMedPubMedCentralCrossRef
90.
go back to reference Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J (2012) Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23:1579–1587PubMedPubMedCentralCrossRef Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J (2012) Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol 23:1579–1587PubMedPubMedCentralCrossRef
91.
go back to reference Huang ZQ, Raska M, Stewart TJ, Reily C, King RG, Crossman DK, Crowley MR, Hargett A, Zhang Z, Suzuki H, Hall S, Wyatt RJ, Julian BA, Renfrow MB, Gharavi AG, Novak J (2016) Somatic mutations modulate autoantibodies against galactose-deficient IgA1 in IgA nephropathy. J Am Soc Nephrol 27:3278–3284PubMedPubMedCentralCrossRef Huang ZQ, Raska M, Stewart TJ, Reily C, King RG, Crossman DK, Crowley MR, Hargett A, Zhang Z, Suzuki H, Hall S, Wyatt RJ, Julian BA, Renfrow MB, Gharavi AG, Novak J (2016) Somatic mutations modulate autoantibodies against galactose-deficient IgA1 in IgA nephropathy. J Am Soc Nephrol 27:3278–3284PubMedPubMedCentralCrossRef
92.
go back to reference Feehally J, Farrall M, Boland A, Gale DP, Gut I, Heath S, Kumar A, Peden JF, Maxwell PH, Morris DL, Padmanabhan S, Vyse TJ, Zawadzka A, Rees AJ, Lathrop M, Ratcliffe PJ (2010) HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 21:1791–1797PubMedPubMedCentralCrossRef Feehally J, Farrall M, Boland A, Gale DP, Gut I, Heath S, Kumar A, Peden JF, Maxwell PH, Morris DL, Padmanabhan S, Vyse TJ, Zawadzka A, Rees AJ, Lathrop M, Ratcliffe PJ (2010) HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 21:1791–1797PubMedPubMedCentralCrossRef
93.
go back to reference Monteiro RC (2005) New insights in the pathogenesis of IgA nephropathy. Nefrologia 25(Suppl 2):82–86PubMed Monteiro RC (2005) New insights in the pathogenesis of IgA nephropathy. Nefrologia 25(Suppl 2):82–86PubMed
94.
go back to reference Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang PH, Tamouza H, Jamin A, Bex-Coudrat J, Gestin A, Boumediene A, Arcos-Fajardo M, England P, Pillebout E, Walker F, Daugas E, Vrtosvnik F, Flamant M, Benhamou M, Cogne M, Moura IC, Monteiro RC (2012) Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 209:793–806PubMedPubMedCentralCrossRef Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang PH, Tamouza H, Jamin A, Bex-Coudrat J, Gestin A, Boumediene A, Arcos-Fajardo M, England P, Pillebout E, Walker F, Daugas E, Vrtosvnik F, Flamant M, Benhamou M, Cogne M, Moura IC, Monteiro RC (2012) Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 209:793–806PubMedPubMedCentralCrossRef
95.
go back to reference Kanamaru Y, Blank U, Monteiro RC (2007) IgA Fc receptor I is a molecular switch that determines IgA activating or inhibitory functions. Contrib Nephrol 157:148–152PubMedCrossRef Kanamaru Y, Blank U, Monteiro RC (2007) IgA Fc receptor I is a molecular switch that determines IgA activating or inhibitory functions. Contrib Nephrol 157:148–152PubMedCrossRef
96.
go back to reference Kanamaru Y, Tamouza H, Pfirsch S, El-Mehdi D, Guerin-Marchand C, Pretolani M, Blank U, Monteiro RC (2007) IgA Fc receptor I signals apoptosis through the FcRgamma ITAM and affects tumor growth. Blood 109:203–211PubMedCrossRef Kanamaru Y, Tamouza H, Pfirsch S, El-Mehdi D, Guerin-Marchand C, Pretolani M, Blank U, Monteiro RC (2007) IgA Fc receptor I signals apoptosis through the FcRgamma ITAM and affects tumor growth. Blood 109:203–211PubMedCrossRef
97.
go back to reference Berthelot L, Robert T, Vuiblet V, Tabary T, Braconnier A, Drame M, Toupance O, Rieu P, Monteiro RC, Toure F (2015) Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int 88:815–822PubMedCrossRef Berthelot L, Robert T, Vuiblet V, Tabary T, Braconnier A, Drame M, Toupance O, Rieu P, Monteiro RC, Toure F (2015) Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int 88:815–822PubMedCrossRef
98.
go back to reference van der Boog PJ, De Fijter JW, Van Kooten C, Van Der Holst R, Van Seggelen A, Van Es LA, Daha MR (2003) Complexes of IgA with FcalphaRI/CD89 are not specific for primary IgA nephropathy. Kidney Int 63:514–521PubMedCrossRef van der Boog PJ, De Fijter JW, Van Kooten C, Van Der Holst R, Van Seggelen A, Van Es LA, Daha MR (2003) Complexes of IgA with FcalphaRI/CD89 are not specific for primary IgA nephropathy. Kidney Int 63:514–521PubMedCrossRef
99.
go back to reference Vuong MT, Hahn-Zoric M, Lundberg S, Gunnarsson I, van Kooten C, Wramner L, Seddighzadeh M, Fernstrom A, Hanson LA, Do LT, Jacobson SH, Padyukov L (2010) Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int 78:1281–1287PubMedCrossRef Vuong MT, Hahn-Zoric M, Lundberg S, Gunnarsson I, van Kooten C, Wramner L, Seddighzadeh M, Fernstrom A, Hanson LA, Do LT, Jacobson SH, Padyukov L (2010) Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int 78:1281–1287PubMedCrossRef
100.
go back to reference Boyd JK, Barratt J (2010) Immune complex formation in IgA nephropathy: CD89 a ‘saint’ or a ‘sinner’? Kidney Int 78:1211–1213PubMedCrossRef Boyd JK, Barratt J (2010) Immune complex formation in IgA nephropathy: CD89 a ‘saint’ or a ‘sinner’? Kidney Int 78:1211–1213PubMedCrossRef
101.
go back to reference Coppo R, Amore A, Gianoglio B, Reyna A, Peruzzi L, Roccatello D, Alessi D, Sena LM (1993) Serum IgA and macromolecular IgA reacting with mesangial matrix components. Contrib Nephrol 104:162–171PubMedCrossRef Coppo R, Amore A, Gianoglio B, Reyna A, Peruzzi L, Roccatello D, Alessi D, Sena LM (1993) Serum IgA and macromolecular IgA reacting with mesangial matrix components. Contrib Nephrol 104:162–171PubMedCrossRef
102.
go back to reference Kokubo T, Hiki Y, Iwase H, Tanaka A, Toma K, Hotta K, Kobayashi Y (1998) Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 9:2048–2054PubMed Kokubo T, Hiki Y, Iwase H, Tanaka A, Toma K, Hotta K, Kobayashi Y (1998) Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 9:2048–2054PubMed
103.
go back to reference Working Group of the International Ig ANN, the Renal Pathology S, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545CrossRef Working Group of the International Ig ANN, the Renal Pathology S, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545CrossRef
104.
go back to reference Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J, Ig ANCWGotIINN, the Renal Pathology S, Conference P (2017) Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int 91:1014–1021PubMedCrossRef Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J, Ig ANCWGotIINN, the Renal Pathology S, Conference P (2017) Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int 91:1014–1021PubMedCrossRef
105.
go back to reference Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Tam KY, Xiao J, Lai FM, Tang SC (2009) Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant 24:62–72PubMedCrossRef Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Tam KY, Xiao J, Lai FM, Tang SC (2009) Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant 24:62–72PubMedCrossRef
106.
go back to reference Hara M, Yanagihara T, Kihara I (2007) Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schönlein–Henoch purpura nephritis. Clin J Am Soc Nephrol 2:231–238 Hara M, Yanagihara T, Kihara I (2007) Cumulative excretion of urinary podocytes reflects disease progression in IgA nephropathy and Schönlein–Henoch purpura nephritis. Clin J Am Soc Nephrol 2:231–238
107.
go back to reference Wang C, Ye Z, Peng H, Tang H, Liu X, Chen Z, Yu X, Lou T (2009) Effect of aggregated immunoglobulin A1 from immunoglobulin a nephropathy patients on nephrin expression in podocytes. Nephrology 14:213–218PubMedCrossRef Wang C, Ye Z, Peng H, Tang H, Liu X, Chen Z, Yu X, Lou T (2009) Effect of aggregated immunoglobulin A1 from immunoglobulin a nephropathy patients on nephrin expression in podocytes. Nephrology 14:213–218PubMedCrossRef
108.
go back to reference Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Lai FM, Tang SC (2008) Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 294:F945–F955PubMedCrossRef Lai KN, Leung JC, Chan LY, Saleem MA, Mathieson PW, Lai FM, Tang SC (2008) Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 294:F945–F955PubMedCrossRef
109.
go back to reference Chan LY, Leung JC, Tsang AW, Tang SC, Lai KN (2005) Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int 67:602–612PubMedCrossRef Chan LY, Leung JC, Tsang AW, Tang SC, Lai KN (2005) Activation of tubular epithelial cells by mesangial-derived TNF-alpha: glomerulotubular communication in IgA nephropathy. Kidney Int 67:602–612PubMedCrossRef
110.
go back to reference Coulon S, Dussiot M, Grapton D, Maciel TT, Wang PH, Callens C, Tiwari MK, Agarwal S, Fricot A, Vandekerckhove J, Tamouza H, Zermati Y, Ribeil JA, Djedaini K, Oruc Z, Pascal V, Courtois G, Arnulf B, Alyanakian MA, Mayeux P, Leanderson T, Benhamou M, Cogne M, Monteiro RC, Hermine O, Moura IC (2011) Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia. Nat Med 17:1456–1465PubMedCrossRef Coulon S, Dussiot M, Grapton D, Maciel TT, Wang PH, Callens C, Tiwari MK, Agarwal S, Fricot A, Vandekerckhove J, Tamouza H, Zermati Y, Ribeil JA, Djedaini K, Oruc Z, Pascal V, Courtois G, Arnulf B, Alyanakian MA, Mayeux P, Leanderson T, Benhamou M, Cogne M, Monteiro RC, Hermine O, Moura IC (2011) Polymeric IgA1 controls erythroblast proliferation and accelerates erythropoiesis recovery in anemia. Nat Med 17:1456–1465PubMedCrossRef
111.
go back to reference Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, Cooper MD, Monteiro RC (2001) Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 194:417–425PubMedPubMedCentralCrossRef Moura IC, Centelles MN, Arcos-Fajardo M, Malheiros DM, Collawn JF, Cooper MD, Monteiro RC (2001) Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 194:417–425PubMedPubMedCentralCrossRef
112.
go back to reference Moura IC, Arcos-Fajardo M, Gdoura A, Leroy V, Sadaka C, Mahlaoui N, Lepelletier Y, Vrtovsnik F, Haddad E, Benhamou M, Monteiro RC (2005) Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 16:2667–2676PubMedCrossRef Moura IC, Arcos-Fajardo M, Gdoura A, Leroy V, Sadaka C, Mahlaoui N, Lepelletier Y, Vrtovsnik F, Haddad E, Benhamou M, Monteiro RC (2005) Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 16:2667–2676PubMedCrossRef
113.
go back to reference Lechner SM, Papista C, Chemouny JM, Berthelot L, Monteiro RC (2016) Role of IgA receptors in the pathogenesis of IgA nephropathy. J Nephrol 29:5–11PubMedCrossRef Lechner SM, Papista C, Chemouny JM, Berthelot L, Monteiro RC (2016) Role of IgA receptors in the pathogenesis of IgA nephropathy. J Nephrol 29:5–11PubMedCrossRef
114.
go back to reference Leung JC, Tsang AW, Chan DT, Lai KN (2000) Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells. J Am Soc Nephrol 11:241–249PubMed Leung JC, Tsang AW, Chan DT, Lai KN (2000) Absence of CD89, polymeric immunoglobulin receptor, and asialoglycoprotein receptor on human mesangial cells. J Am Soc Nephrol 11:241–249PubMed
115.
go back to reference Matousovic K, Novak J, Yanagihara T, Tomana M, Moldoveanu Z, Kulhavy R, Julian BA, Konecny K, Mestecky J (2006) IgA-containing immune complexes in the urine of IgA nephropathy patients. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc - Eur Renal Assoc 21:2478–2484CrossRef Matousovic K, Novak J, Yanagihara T, Tomana M, Moldoveanu Z, Kulhavy R, Julian BA, Konecny K, Mestecky J (2006) IgA-containing immune complexes in the urine of IgA nephropathy patients. Nephrol Dial Transplant: Off Publ Eur Dial Transplant Assoc - Eur Renal Assoc 21:2478–2484CrossRef
116.
go back to reference McAdoo SP, Bhangal G, Page T, Cook HT, Pusey CD, Tam FW (2015) Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. Kidney Int 88:52–60PubMedPubMedCentralCrossRef McAdoo SP, Bhangal G, Page T, Cook HT, Pusey CD, Tam FW (2015) Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. Kidney Int 88:52–60PubMedPubMedCentralCrossRef
117.
go back to reference Smith J, McDaid JP, Bhangal G, Chawanasuntorapoj R, Masuda ES, Cook HT, Pusey CD, Tam FW (2010) A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J Am Soc Nephrol 21:231–236PubMedPubMedCentralCrossRef Smith J, McDaid JP, Bhangal G, Chawanasuntorapoj R, Masuda ES, Cook HT, Pusey CD, Tam FW (2010) A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis. J Am Soc Nephrol 21:231–236PubMedPubMedCentralCrossRef
118.
go back to reference McAdoo SP, Reynolds J, Bhangal G, Smith J, McDaid JP, Tanna A, Jackson WD, Masuda ES, Cook HT, Pusey CD, Tam FW (2014) Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN. J Am Soc Nephrol 25:2291–2302PubMedPubMedCentralCrossRef McAdoo SP, Reynolds J, Bhangal G, Smith J, McDaid JP, Tanna A, Jackson WD, Masuda ES, Cook HT, Pusey CD, Tam FW (2014) Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN. J Am Soc Nephrol 25:2291–2302PubMedPubMedCentralCrossRef
119.
go back to reference Kim MJ, Schaub S, Molyneux K, Koller MT, Stampf S, Barratt J (2016) Effect of immunosuppressive drugs on the changes of serum galactose-deficient IgA1 in patients with IgA nephropathy. PLoS One 11:e0166830PubMedPubMedCentralCrossRef Kim MJ, Schaub S, Molyneux K, Koller MT, Stampf S, Barratt J (2016) Effect of immunosuppressive drugs on the changes of serum galactose-deficient IgA1 in patients with IgA nephropathy. PLoS One 11:e0166830PubMedPubMedCentralCrossRef
120.
go back to reference Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J (2015) Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol 26:1503–1512PubMedPubMedCentralCrossRef Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J (2015) Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol 26:1503–1512PubMedPubMedCentralCrossRef
121.
go back to reference Miyazaki R, Kuroda M, Akiyama T, Otani I, Tofuku Y, Takeda R (1984) Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy. Clin Nephrol 21:335–340PubMed Miyazaki R, Kuroda M, Akiyama T, Otani I, Tofuku Y, Takeda R (1984) Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy. Clin Nephrol 21:335–340PubMed
122.
go back to reference Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E (1987) Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int 31:820–829PubMedCrossRef Rauterberg EW, Lieberknecht HM, Wingen AM, Ritz E (1987) Complement membrane attack (MAC) in idiopathic IgA-glomerulonephritis. Kidney Int 31:820–829PubMedCrossRef
123.
go back to reference Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M, Fujita T (1998) Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 13:1984–1990PubMedCrossRef Endo M, Ohi H, Ohsawa I, Fujita T, Matsushita M, Fujita T (1998) Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 13:1984–1990PubMedCrossRef
124.
go back to reference Hisano S, Matsushita M, Fujita T, Endo Y, Takebayashi S (2001) Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am J Kidney Dis 38:1082–1088PubMedCrossRef Hisano S, Matsushita M, Fujita T, Endo Y, Takebayashi S (2001) Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am J Kidney Dis 38:1082–1088PubMedCrossRef
125.
go back to reference Matsuda M, Shikata K, Wada J, Sugimoto H, Shikata Y, Kawasaki T, Makino H (1998) Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron 80:408–413PubMedCrossRef Matsuda M, Shikata K, Wada J, Sugimoto H, Shikata Y, Kawasaki T, Makino H (1998) Deposition of mannan binding protein and mannan binding protein-mediated complement activation in the glomeruli of patients with IgA nephropathy. Nephron 80:408–413PubMedCrossRef
126.
go back to reference Maeng YI, Kim MK, Park JB, Cho CH, Oh HK, Sung WJ, Park KK (2013) Glomerular and tubular C4d depositions in IgA nephropathy: relations with histopathology and with albuminuria. Int J Clin Exp Pathol 6:904–910PubMedPubMedCentral Maeng YI, Kim MK, Park JB, Cho CH, Oh HK, Sung WJ, Park KK (2013) Glomerular and tubular C4d depositions in IgA nephropathy: relations with histopathology and with albuminuria. Int J Clin Exp Pathol 6:904–910PubMedPubMedCentral
127.
go back to reference Espinosa M, Ortega R, Gomez-Carrasco JM, Lopez-Rubio F, Lopez-Andreu M, Lopez-Oliva MO, Aljama P (2009) Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol Dial Transplant 24:886–891PubMedCrossRef Espinosa M, Ortega R, Gomez-Carrasco JM, Lopez-Rubio F, Lopez-Andreu M, Lopez-Oliva MO, Aljama P (2009) Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol Dial Transplant 24:886–891PubMedCrossRef
128.
go back to reference Espinosa M, Ortega R, Sanchez M, Segarra A, Salcedo MT, Gonzalez F, Camacho R, Valdivia MA, Cabrera R, Lopez K, Pinedo F, Gutierrez E, Valera A, Leon M, Cobo MA, Rodriguez R, Ballarin J, Arce Y, Garcia B, Munoz MD, Praga M, Spanish Group for Study of Glomerular D (2014) Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 9:897–904PubMedPubMedCentralCrossRef Espinosa M, Ortega R, Sanchez M, Segarra A, Salcedo MT, Gonzalez F, Camacho R, Valdivia MA, Cabrera R, Lopez K, Pinedo F, Gutierrez E, Valera A, Leon M, Cobo MA, Rodriguez R, Ballarin J, Arce Y, Garcia B, Munoz MD, Praga M, Spanish Group for Study of Glomerular D (2014) Association of C4d deposition with clinical outcomes in IgA nephropathy. Clin J Am Soc Nephrol 9:897–904PubMedPubMedCentralCrossRef
129.
go back to reference Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR (2006) Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17:1724–1734PubMedCrossRef Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR (2006) Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17:1724–1734PubMedCrossRef
130.
go back to reference Zhu L, Zhai YL, Wang FM, Hou P, Lv JC, Xu DM, Shi SF, Liu LJ, Yu F, Zhao MH, Novak J, Gharavi AG, Zhang H (2015) Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy. J Am Soc Nephrol 26:1195–1204PubMedCrossRef Zhu L, Zhai YL, Wang FM, Hou P, Lv JC, Xu DM, Shi SF, Liu LJ, Yu F, Zhao MH, Novak J, Gharavi AG, Zhang H (2015) Variants in complement factor H and complement factor H-related protein genes, CFHR3 and CFHR1, affect complement activation in IgA nephropathy. J Am Soc Nephrol 26:1195–1204PubMedCrossRef
131.
go back to reference Xie J, Kiryluk K, Li Y, Mladkova N, Zhu L, Hou P, Ren H, Wang W, Zhang H, Chen N, Gharavi AG (2016) Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese. J Am Soc Nephrol 27:3187–3194PubMedPubMedCentralCrossRef Xie J, Kiryluk K, Li Y, Mladkova N, Zhu L, Hou P, Ren H, Wang W, Zhang H, Chen N, Gharavi AG (2016) Fine mapping implicates a deletion of CFHR1 and CFHR3 in protection from IgA nephropathy in Han Chinese. J Am Soc Nephrol 27:3187–3194PubMedPubMedCentralCrossRef
132.
go back to reference Ring T, Pedersen BB, Salkus G, Goodship TH (2015) Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J 8:489–491PubMedPubMedCentralCrossRef Ring T, Pedersen BB, Salkus G, Goodship TH (2015) Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum? Clin Kidney J 8:489–491PubMedPubMedCentralCrossRef
133.
go back to reference Rosenblad T, Rebetz J, Johansson M, Bekassy Z, Sartz L, Karpman D (2014) Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 29:2225–2228PubMedCrossRef Rosenblad T, Rebetz J, Johansson M, Bekassy Z, Sartz L, Karpman D (2014) Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 29:2225–2228PubMedCrossRef
Metadata
Title
New insights into the pathogenesis of IgA nephropathy
Authors
See Cheng Yeo
Chee Kay Cheung
Jonathan Barratt
Publication date
01-05-2018
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 5/2018
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-017-3699-z

Other articles of this Issue 5/2018

Pediatric Nephrology 5/2018 Go to the issue